In this 2nd episode, our co-hosts discuss the use of a macro-scale material to co-deliver GMCSF and CpG, both APC stimulating agents, as well as AML antigens to kill AML cells.
GUEST: Alex Najibi is now a postdoctoral fellow at Harvard School of Engineering and Applied Sciences, studying bioengineering in David Mooney's lab.
Original study => https://pubmed.ncbi.nlm.nih.gov/31937942/
Thanks for listening! Let’s stay in touch:
- Tweet us at @ImmunoTalks
- Share our episodes on LinkedIN and Instagram
- Email us at [email protected]
06/02/22 • 23 min
Immunotherapy Talks with ACIR - #2 - A biomaterial-based vaccine
Transcript
Episode #2- A biomaterial-based vaccine
[00:00:00] Ute Burkhardt: Welcome to Immunotherapy Talks with ACIR. Reading research can be complicated, but it doesn't have to be. ACIR digests the latest in cancer immunotherapy research into bite-sized pieces to help you stay on top of the. I'm Ute Burkhardt,
[00:00:22] Nathan Suek: And I am Nathan Suek in this podcast, we'll discuss important and current questions in cancer immunology and
Generate a badge
Get a badge for your website that links back to this episode
<a href="https://goodpods.com/podcasts/immunotherapy-talks-with-acir-427335/2-a-biomaterial-based-vaccine-58794639"> <img src="https://storage.googleapis.com/goodpods-images-bucket/badges/generic-badge-1.svg" alt="listen to #2 - a biomaterial-based vaccine on goodpods" style="width: 225px" /> </a>
Copy